Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full NewsEli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results in patients with the skin disease and obesity in a...
Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.
Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.
South Carolina reported a surge to 962 measles cases on Tuesday, state health data showed, including 12 additional infections since Friday, as officials warned the widening...
As currently written, the instructions could potentially lead to delayed treatment of high glucose levels.
An expansion of higher-level neonatal care has been observed in urban hospitals in the US over the years, whereas rural hospitals have faced a decline in such care capacity, per a recent study.
1.
Video: Liver transplant for patients with advanced colorectal cancer
2.
Optimizing Sequencing of BCMA-Directed Therapies in Myeloma
3.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
4.
In cancer survivors, loneliness is associated with a higher risk of death.
5.
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic
1.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
2.
Unmasking the Subtle Symptoms of Colon Cancer
3.
Demystifying the Mentzer Index: Understanding Its Importance in Inventory Management
4.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
5.
The Future of Hemophilia Treatment: Long-Acting Therapies and Gene Editing
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
Navigating the Complexities of Ph Negative ALL - Part VII
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation